Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Narrative Our study will define the immunogenicity of Covid-19 booster vaccinations in patients with a malignant diagnosis. The first study cohort will focus on detectable immunogenicity as defined by standard antibody assays as well as T cell and viral neutralization assays from FDA authorized booster dosing in patients with a cancer diagnosis, while the second study cohort will involve a randomized study to assess the superiority of a “switch” versus conventional booster strategy. These studies will provide pivotal information to best protect our most vulnerable patient populations with a cancer diagnosis.